Anúncio
Anúncio
ARQT
Arcutis Biotherapeutics, Inc. Common Stock
28.96
USDPatrocinado
-0.07
-0.26%
02 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
28.64
-0.32
-1.10%
Relatórios de Lucros ARQT
Rácio de surpresa positiva
ARQT separação 20 de 24 últimas estimativas.
83%
Próximo Relatório
Data do Próximo Relatório
10 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$112.49M
/$0.06
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+13.37%
/--
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+57.64%
/-166.67%
Arcutis Biotherapeutics, Inc. Common Stock earnings per share and revenue
On 28 de out. de 2025, ARQT reported earnings of 0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.10 USD, resulting in a 158.88% surprise. Revenue reached 99.22 milhão, compared to an expected 88.72 milhão, with a 11.84% difference. The market reacted with a +27.04% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of 0.06 USD, with revenue projected to reach 112.49 milhão USD, implying an aumentar of 0.00% EPS, and aumentar of 13.37% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Arcutis Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Arcutis Biotherapeutics, Inc. Common Stock reported EPS of $0.06, beating estimates by 158.88%, and revenue of $99.22M, 11.84% above expectations.
How did the market react to Arcutis Biotherapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 27.04%, changed from $19.64 before the earnings release to $24.95 the day after.
When is Arcutis Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 10 de fev. de 2026.
What are the forecasts for Arcutis Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 10
analistas, Arcutis Biotherapeutics, Inc. Common Stock is expected to report EPS of $0.06 and revenue of $112.49M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio